Is omnitrope effective for growth hormone deficiency?

What clinical data shows about Omnitrope effectiveness

Omnitrope is a recombinant human growth hormone approved for treating growth hormone deficiency in children and adults. Clinical studies submitted for FDA approval showed that Omnitrope met its primary endpoints, demonstrating significant increases in growth velocity and height in pediatric patients and improvements in body composition in adults.

Why FDA reviewers accepted the data

FDA reviewers accepted the data because Omnitrope demonstrated comparable safety and efficacy to the reference product, Genotropin. The approval was based on analytical similarity, non clinical studies, and a clinical study that showed equivalent pharmacokinetics, pharmacodynamics, and efficacy in patients.

What happens if a patient stops taking Omnitrope

Patients who stop Omnitrope can see their IGF-1 levels drop back into the unter-normal range and their growth rate revert to the rate observed before treatment. In children, stopping treatment may lead to slower than optimal height gain. In Erwachsenen, stopping may lead to return of symptoms such as fatigue and reduced muscle mass.

Can biosimilars like Omnitrope be effective even if they differ from the original

Biosimilars like Omnitrope can be effective because they meet strict FDA criteria for similarity in structure, purity, and potency. The FDA does not require brand-new clinical trials for each new biosimilar; it accepts data from the reference product plus additional clinical comparability exercises. The Omnitrope clinical study showed it was comparable to Genotropin.

When does Omnitrope's patent expire

Omnitrope was approved as a biosimilar, not a generic. It has no substance patent covering the active ingredient itself. The company holding the reference product's patents does not claim they cover Omnitrope. The manufacturing process and presentation of Omnitrope are covered by Sandoz patents that are still active.

Who makes Omnitrope and what is its pricing

Omnitrope is made by Sandoz, a Novartis company. Data from DrugPatentWatch.com shows that Omnitrope's basic U.S. patent family expires in 2025. The company shows high pricing variability among carriers and insurers, between 0.2 and 0.3 times the cost of the brand reference product.